CER Daily Newsfeed

Video: Reshaping Rx: Navigating 2025 Drug Pricing Policies—Recording

(7/2, Laura Joszt, MA, The American Journal of Managed Care) “...Ryan Haumschild, PharmD, MBA, MS, CPEL, vice president of pharmacy at Emory Healthcare and Winship Cancer Institute, moderated the discussion on June 26 with: John O'Brien, PharmD, MPH, president and CEO at National Pharmaceutical Council...O'Brien outlined the importance of addressing broader systemic issues in health care, while Oubre and Favaro discussed the challenges of biosimilar adoption and the need for targeted solutions to address payer issues.” View Video

Trump’s Ongoing Tariff Chaos Will Make Medications Less Affordable And Harder To Find

(7/2, Aaron S. Kesselheim, Jerry Avorn, Health Affairs Forefront) comments “...In the US any negotiation that does occur is conducted in secret, often by pharmacy benefit managers (PBMs), and then implemented in ways that leave patients with high out-of-pocket costs. By contrast, basing a drug’s price on its actual clinical worth would reward meaningful innovation by allowing the most useful products to earn substantial revenues, while expensive drugs with no clinical advantage wouldn’t command excessive prices. Those obvious solutions appear nowhere in Trump’s Executive Orders or his plans for across-the-board pharmaceutical tariffs or ‘most favored nation’ pricing, which essentially would attempt to outsource such evaluation to other countries.” Full

Addressing Population Gaps in Therapy Adoption: Using Real-World Data to Bridge the Clinical Trial Divide

(7/1, Noah Nasser, Applied Clinical Trials) comments “...Expanding adoption requires more than just education or outreach. It requires generating evidence that supports the therapy’s effectiveness in real-world populations that better reflect day to day clinical practice. Unlike guideline inclusion, where formal committee review requires structured evidence, driving broader adoption often hinges on physicians seeing outcomes in patients who reflect their day-to-day practice.” Full

EMA Reports Significant Growth in Use of Real-World Evidence for Medicines Regulation

(7/2, Katie McCool, The Evidence Base) reports “The European Medicines Agency (EMA) has released its third annual report on the use of real-world evidence (RWE) in medicines regulation, covering the period from February 2024 to February 2025. The report highlights significant progress in embedding RWE into regulatory decision-making, with 59 studies conducted, almost 48% more than the previous year. Of these studies, 33 were completed and 26 are ongoing, supporting a wide range of safety, utilization, and epidemiological assessments.” Full

Industry Criticizes Dutch Decision To Slash PARP Inhibitor Reimbursement

(7/2, Francesca Bruce, Pink Sheet) reports “...ZIN, the Dutch health technology assessment body, estimates that the number of patients eligible for treatment with a PARP inhibitor will be halved following a reassessment of drugs in the class.” Subscription Required